441 related articles for article (PubMed ID: 21996747)
1. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
2. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.
Zhu P; Davis M; Blackwelder AJ; Bachman N; Liu B; Edgerton S; Williams LL; Thor AD; Yang X
Cancer Prev Res (Phila); 2014 Feb; 7(2):199-210. PubMed ID: 24322659
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
4. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
[TBL] [Abstract][Full Text] [Related]
6. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.
Vaillant F; Asselin-Labat ML; Shackleton M; Forrest NC; Lindeman GJ; Visvader JE
Cancer Res; 2008 Oct; 68(19):7711-7. PubMed ID: 18829523
[TBL] [Abstract][Full Text] [Related]
7. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
[TBL] [Abstract][Full Text] [Related]
8. Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.
Novitskiy SV; Forrester E; Pickup MW; Gorska AE; Chytil A; Aakre M; Polosukhina D; Owens P; Yusupova DR; Zhao Z; Ye F; Shyr Y; Moses HL
Breast Cancer Res; 2014 Oct; 16(5):425. PubMed ID: 25280532
[TBL] [Abstract][Full Text] [Related]
9. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression.
Gupta P; Srivastava SK
Oncotarget; 2014 Apr; 5(7):1812-28. PubMed ID: 24729020
[TBL] [Abstract][Full Text] [Related]
12. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
[TBL] [Abstract][Full Text] [Related]
13. Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells.
Rahal OM; Nie L; Chan LC; Li CW; Hsu YH; Hsu J; Yu D; Hung MC
Am J Cancer Res; 2015; 5(12):3624-34. PubMed ID: 26885451
[TBL] [Abstract][Full Text] [Related]
14. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
15. Multipotent PI-MECs are the true targets of MMTV-neu tumorigenesis.
Wagner KU; Booth BW; Boulanger CA; Smith GH
Oncogene; 2013 Mar; 32(10):1338. PubMed ID: 23045277
[No Abstract] [Full Text] [Related]
16. FGFR2 promotes breast tumorigenicity through maintenance of breast tumor-initiating cells.
Kim S; Dubrovska A; Salamone RJ; Walker JR; Grandinetti KB; Bonamy GM; Orth AP; Elliott J; Porta DG; Garcia-Echeverria C; Reddy VA
PLoS One; 2013; 8(1):e51671. PubMed ID: 23300950
[TBL] [Abstract][Full Text] [Related]
17. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
18. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population.
Pratt MA; Tibbo E; Robertson SJ; Jansson D; Hurst K; Perez-Iratxeta C; Lau R; Niu MY
Oncogene; 2009 Jul; 28(30):2710-22. PubMed ID: 19483731
[TBL] [Abstract][Full Text] [Related]
19. Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium.
Tarulli GA; De Silva D; Ho V; Kunasegaran K; Ghosh K; Tan BC; Bulavin DV; Pietersen AM
Breast Cancer Res; 2013 Jan; 15(1):R10. PubMed ID: 23369183
[TBL] [Abstract][Full Text] [Related]
20. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]